Psoriatic Arthritis Trial, Recruiting (NCT07128472)

Psoriatic Arthritis Trial, Recruiting NCT07128472 Sponsor: South Valley University Condition: Psoriatic Arthritis

Printed from Voxsanity (voxsanity.com.au) — NCT07128472 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Psoriatic Arthritis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been clinically diagnosed with psoriasis for at least 6 months, with a severity score greater than 10 on a standard psoriasis measurement scale, skin involvement covering more than 10% of the body surface, and who also have psoriatic arthritis (joint inflammation related to psoriasis).

Who may not be able to join:

People who have other autoimmune or inflammatory conditions, such as rheumatoid arthritis or lupus.
People who are pregnant or breastfeeding.
People who are currently receiving any treatment other than Humira (adalimumab).
People who have a known genetic disorder that affects how the immune system works.
People who have received any treatment other than Humira in the past 6 months.
People who have an active infection, including tuberculosis, hepatitis B or C, or HIV.
People for whom Humira (adalimumab) is considered medically unsuitable or contraindicated (confirm with trial site).
People who have kidney (renal) or vascular (blood vessel) disease.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Moustafa Adam Ali El Taieb, Professor, Dermatology, Venereology and Andrology. Faculty of Medicine,Qena University

Phone: +201119814470

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07128472

Sponsor: South Valley University

Phase: Not Applicable

Status: Recruiting

Condition: Psoriatic Arthritis

Trial contact: +201119814470

More information: https://clinicaltrials.gov/study/NCT07128472

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been clinically diagnosed with psoriasis for at least 6 months, with a severity score greater than 10 on a standard psoriasis measurement scale, skin involvement covering more than 10% of the body surface, and who also have psoriatic arthritis (joint inflammation related to psoriasis).

Who may not be able to join:

People who have other autoimmune or inflammatory conditions, such as rheumatoid arthritis or lupus.
People who are pregnant or breastfeeding.
People who are currently receiving any treatment other than Humira (adalimumab).
People who have a known genetic disorder that affects how the immune system works.
People who have received any treatment other than Humira in the past 6 months.
People who have an active infection, including tuberculosis, hepatitis B or C, or HIV.
People for whom Humira (adalimumab) is considered medically unsuitable or contraindicated (confirm with trial site).
People who have kidney (renal) or vascular (blood vessel) disease.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

South Valley University

Registry

ClinicalTrials.gov

Start date

1 August 2025

Est. completion

20 January 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Treatment of Psoriasis and Psoriatic Arthritis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov